In the News: China’s Record Clinical Drug Trial Registrations; China Issues AI Agent Identity Standards; and CATL’s Europe Battery-Swapping Network

China’s clinical drug trial registrations exceed the U.S.’s, causing concerns| SAMR releases national standards for AI agent interconnection to establish a unified identity framework | CATL to work with U.K.-based Octopus Energy to launch battery-swapping stations in Europe

By Jeffrey Tse

In the News: China’s Record Clinical Drug Trial Registrations; China Issues AI Agent Identity Standards; and CATL’s Europe Battery-Swapping Network

China’s Clinical Drug Trial Registrations Hit Record High

Statistics show that the number of clinical drug trials in China hit a record high last year.

There were 5,215 clinical drug trials last year, more than double that of 2020, according to a report released by the National Medical Products Administration.

Exclusive Content

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

Access to 3000+ essential documents, including key PRC laws translated into English
Newsletters with business-critical and sector-specific updates
Premium mobile access with timely analysis on China’s fast-changing market

Already a Subscriber? Log In Here

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)